Home page

The first phase of the vaccine industrialization project was successfully completed

2017-08-30

Author: Internet

The human vaccine industrialization project ofAb&B Bio-Tech Co.,Ltd（Ab&B Bio） covers an area of 70 acres and has a planned construction area of 50,000 square meters. The first phase of construction projects includes: R&D complex building, production workshop 1, animal room, central laboratory and other five The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.

The human vaccine industrialization project of Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） covers an area of 70 acres and has a planned construction area of 50,000 square meters. The first phase of construction projects includes: R&D complex building, production workshop 1, animal room, central laboratory and other five The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.

Phase I clinical kick-off meeting

Qu Futian, then secretary of the Taizhou Municipal Party Committee, went to the company for investigation

06-30

2026

The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.

Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

05-08

2026

The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.

Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

03-13

2026

Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global

On March 13, 2026, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines with Watson Biotech Hong Kong Limited (hereinafter referred to as "Watson Hong Kong") in Taizhou. Both parties announced that they will jointly promote Ab&B Bio's independently developed influenza virus subunit vaccine to set sail overseas. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.

Customer Message

You can leave us your needs or suggestions, and we will reply to you as soon as we receive them.

Need more help?

Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.

Online Message

CONTACT

E-Mail:
yue.peng@yitherbiotech.com
Hotline:
+86-021-61639751
Address:
No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai

QUICK LINKS

Home
Product
About us
News
Contact

PRODUCTS

Listed products
Products under development

Business license